Taspoglutide
Taspoglutide is a former experimental drug, a glucagon-like peptide-1 agonist, that was under investigation for treatment of type 2 diabetes and being codeveloped by Ipsen and Roche.
Initially, phase II trials reported it was effective and well tolerated.
Of the eight planned phase III clinical trials of weekly taspoglutide, at least five were active in 2009. Preliminary results in early 2010 were favourable.
In September 2010 Roche halted Phase III clinical trials due to instances of serious hypersensitivity reactions and gastrointestinal side effects.
no new trials have been registered since 2010.
Chemistry
Taspoglutide is the peptide with the sequence His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Aib-Arg-NH2, where Aib is 2-aminoisobutyric acid.In other words, it is the 8--35--36-L-argininamide derivative of the amino acid sequence 7–36 of human glucagon-like peptide I.